Plexus (PLXS) has drawn investor attention after reporting fiscal third quarter results that exceeded revenue and adjusted earnings expectations, alongside 31 new manufacturing program wins and fresh guidance pointing to continued revenue and margin growth.

Plexus shares have pulled back recently, with a 30 day share price return of 8.64% and a 90 day return of 5.01%. However, the year to date share price return of 65.11% and 1 year total shareholder return of 100.82% still point to strong momentum building around the story. This is particularly the case as the latest earnings beat, upbeat guidance issued on 29 July 2026, and ongoing buybacks keep the focus on growth and capital returns.

If Plexus’s move has you looking beyond a single stock, this is a good moment to broaden your watchlist and review the 18 top founder-led companies

Plexus is now trading near record levels after a strong run and upbeat guidance, yet the valuation does not fully reflect some estimates of intrinsic value. Does that balance of risk and potential reward still favour new buyers?

Most Popular Narrative: 14.3% Undervalued

Plexus is trading at a last close of $251.34, while the most followed narrative sets fair value at $293.25, which frames the current valuation gap as meaningful.

The company's increasing success in winning programs in high-margin, complex sectors such as healthcare/life sciences, aerospace, and defense (including strong defense pipeline in Europe and record sector wins), is shifting the revenue mix toward segments with higher pricing power and more stable, long-term contracts. This should positively impact both revenue consistency and net margin expansion.

Want to see what sits behind that confidence in Plexus? The narrative leans heavily on sustained revenue growth, modest margin gains, and a rich future earnings multiple. It may be useful to understand which specific long term targets have been built into that fair value path.

Result: Fair Value of $293.25 (UNDERVALUED)

However, Plexus holders still need to watch for demand pushbacks in key sectors, as well as any pressure on margins from rising costs or new facility ramp ups.

Next Steps

With both risks and rewards in play for Plexus, this is a good time to review the details yourself and decide how the balance looks. To see the full picture that other investors are weighing up, take a close look at the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Plexus?

If Plexus has sharpened your focus on quality, do not stop here. Use the screener to explore more stocks that align with your goals.

• Target dependable compounding potential with companies that consistently return cash to shareholders through 9 dividend fortresses.
• Focus on opportunities where price and fundamentals align by scanning the 55 high quality undervalued stocks.
• Prioritise capital protection and seek steadier participation in the market using the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.